Total Payments
$1,136
2024 Payments
$531.52
Companies
21
Transactions
44
Medicare Patients
1,634
Medicare Billing
$171,196
Payment Breakdown by Category
Food & Beverage$1,088 (95.8%)
Education$47.55 (4.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,088 | 41 | 95.8% |
| Education | $47.55 | 3 | 4.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $237.23 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $124.36 | 5 | $0 (2024) |
| PFIZER INC. | $116.00 | 2 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $97.03 | 5 | $0 (2023) |
| Exelixis Inc. | $82.14 | 1 | $0 (2017) |
| GlaxoSmithKline, LLC. | $63.41 | 3 | $0 (2024) |
| SpringWorks Therapeutics, Inc. | $46.71 | 2 | $0 (2024) |
| ABBVIE INC. | $40.56 | 2 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $39.16 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $31.67 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $531.52 | 23 | Gilead Sciences, Inc. ($138.33) |
| 2023 | $227.65 | 12 | Pharmacyclics LLC, An AbbVie Company ($66.09) |
| 2022 | $30.94 | 2 | Pharmacyclics LLC, an AbbVie Company ($30.94) |
| 2018 | $240.53 | 4 | Gilead Sciences, Inc. ($98.90) |
| 2017 | $104.93 | 3 | Exelixis Inc. ($82.14) |
All Payment Transactions
44 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: DESMOID TUMORS | ||||||
| 11/20/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), YONSA | Food and Beverage | In-kind items and services | $39.16 | General |
| Category: Oncology | ||||||
| 11/13/2024 | SERVIER PHARMACEUTICALS LLC | Voranigo (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Oncology | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Oncology | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $41.37 | General |
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.72 | General |
| 10/03/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.05 | General |
| 09/05/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Oncology | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $30.19 | General |
| Category: Oncology | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Oncology | ||||||
| 07/30/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: DESMOID TUMORS | ||||||
| 07/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.13 | General |
| 06/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.40 | General |
| 05/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.92 | General |
| 05/09/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.53 | General |
| 03/08/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.58 | General |
| 02/21/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Oncology | ||||||
| 02/09/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: ONCOLOGY | ||||||
| 02/02/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2023 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 592 | 2,567 | $123,741 | $49,174 |
| 2022 | 4 | 354 | 632 | $103,444 | $42,051 |
| 2021 | 4 | 323 | 611 | $99,521 | $41,850 |
| 2020 | 3 | 365 | 705 | $111,012 | $38,122 |
Total Patients
1,634
Total Services
4,515
Medicare Billing
$171,196
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 47 | 104 | $19,630 | $9,961 | 50.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 26 | 78 | $22,776 | $7,612 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 57 | 92 | $12,236 | $6,087 | 49.7% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 17 | 61 | $4,270 | $4,655 | 109.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 39 | 53 | $9,381 | $3,516 | 37.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $6,270 | $2,763 | 44.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 55 | 269 | $4,493 | $2,222 | 49.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 59 | 63 | $7,308 | $2,211 | 30.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 22 | $3,960 | $2,064 | 52.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 54 | 202 | $7,151 | $2,061 | 28.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 53 | 253 | $6,687 | $1,907 | 28.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 19 | 158 | $5,435 | $1,811 | 33.3% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 22 | 37 | $2,388 | $655.86 | 27.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 41 | $1,558 | $444.85 | 28.6% |
| 83735 | Magnesium level | Office | 2023 | 16 | 64 | $1,458 | $403.71 | 27.7% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 15 | 350 | $7,028 | $258.23 | 3.7% |
| 86704 | Hepatitis b core antibody measurement | Office | 2023 | 14 | 15 | $453.75 | $177.15 | 39.0% |
| 87340 | Detection test by immunoassay technique for hepatitis b surface antigen | Office | 2023 | 14 | 15 | $390.00 | $151.80 | 38.9% |
| 86706 | Hepatitis b surface antibody measurement | Office | 2023 | 14 | 14 | $378.00 | $147.42 | 39.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 20 | 654 | $490.50 | $64.14 | 13.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 128 | 357 | $62,118 | $26,399 | 42.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 143 | 192 | $21,888 | $8,717 | 39.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 58 | 58 | $16,588 | $5,781 | 34.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 25 | 25 | $2,850 | $1,154 | 40.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 110 | 332 | $57,336 | $24,957 | 43.5% |
About Dr. Kathrine Cooper, MD
Dr. Kathrine Cooper, MD is a Hematology & Oncology healthcare provider based in Reed City, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2009. The National Provider Identifier (NPI) number assigned to this provider is 1447487053.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kathrine Cooper, MD has received a total of $1,136 in payments from pharmaceutical and medical device companies, with $531.52 received in 2024. These payments were reported across 44 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,088).
As a Medicare-enrolled provider, Cooper has provided services to 1,634 Medicare beneficiaries, totaling 4,515 services with total Medicare billing of $171,196. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Reed City, MI
- Active Since 06/22/2009
- Last Updated 04/25/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1447487053
Products in Payments
- IMBRUVICA (Drug) $121.99
- Zydelig (Drug) $98.90
- IBRANCE (Drug) $98.10
- Cabometyx (Drug) $82.14
- OJJAARA (Drug) $63.41
- OGSIVEO (Drug) $46.71
- ENHERTU (Biological) $44.84
- Odomzo (Drug) $39.16
- LYNPARZA (Drug) $38.15
- KEYTRUDA (Biological) $31.67
- OPDIVO (Biological) $30.20
- LIBTAYO (Biological) $27.43
- VERZENIO (Drug) $23.90
- Voranigo (Drug) $23.48
- RYBREVANT (Drug) $23.43
- OPDUALAG (Drug) $22.17
- Aliqopa (Drug) $19.63
- KIMMTRAK (Drug) $19.30
- INLYTA (Drug) $17.90
- VENCLEXTA (Drug) $15.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.